Amgen Names Arvind Sood Vice President, Investor Relations
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 16, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the appointment of Arvind Sood to the position of vice
president, Investor Relations. Sood will be responsible for
developing, implementing and managing a comprehensive and strategic
global investor relations program.
"Arvind brings more than 20 years of domestic and international
pharmaceutical industry experience to Amgen," said Richard Nanula,
Amgen's executive vice president and chief financial officer. "I am
confident that he will be a great asset in effectively communicating
to Amgen's investment audiences."
Sood joins Amgen from Aventis S.A. where he served as senior vice
president for Investor Relations and Financial Communications and was
responsible for overseeing global investor relations activities for
the company. Sood also worked at Rhone-Poulenc S.A, before
Rhone-Poulenc's merger with Hoechst A.G. to form Aventis, where he
progressed through positions of increasing responsibility in investor
relations including his role of senior vice president, Investor
Relations and Financial Communications. Prior to his tenure at Aventis
and Rhone-Poulenc, Sood spent more than 12 years at the Upjohn Company
of Kalamazoo, Michigan, where he served in several functions including
pharmaceutical sales, marketing and investor relations.
Sood was recognized as the "Best IR Professional" in 2004 amongst
all European pharmaceutical companies by Institutional Investor and
commended in 2002 by IR Magazine for "Best Investor Relations by a
European Company in the U.S. Market." He obtained his undergraduate
degree in Business Administration from Western Michigan University and
his master's degree in Business Administration from the Graduate
School of Business at Central Michigan University.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (media)
Laura Biswas, 805-447-1060 (investors)